Sirolimus CAS:53123-88-9

Immunosuppression: Sirolimus is used to prevent organ rejection following kidney transplantation. It is often prescribed in combination with other immunosuppressive agents to reduce the risk of rejection and improve graft survival. Coronary Stent Coating: In cardiology, sirolimus is utilized in drug-eluting stents to prevent restenosis (re-narrowing) of arteries after angioplasty, aiding in the maintenance of vessel patency and reducing the need for repeat interventions. Treatment of Lymphangioleiomyomatosis (LAM): Sirolimus has been approved for the treatment of LAM, a rare lung disease, to improve lung function and slow disease progression. Cancer Therapy: It is used in the treatment of certain types of cancer, including renal cell carcinoma and postmenopausal women with advanced breast cancer, demonstrating antiproliferative effects. Dermatologic Conditions: Sirolimus has been investigated for its potential in treating various dermatologic conditions such as psoriasis, atopic dermatitis, and angiofibromas associated with tuberous sclerosis complex. Vascular Grafts: In vascular surgery, sirolimus-coated grafts are used to inhibit intimal hyperplasia and promote better long-term patency in vascular reconstructions. Investigational Therapies: Research is ongoing on the use of sirolimus in autoimmune diseases, such as systemic lupus erythematosus, and in the field of regenerative medicine and tissue engineering. In summary, sirolimus plays a crucial role in transplantation medicine, cardiology, oncology, and various therapeutic areas due to its immunosuppressant and antiproliferative properties, contributing to improved patient outcomes and the advancement of medical treatment.